Data indicate that one in five patients with cancer might be at risk for nonmedical opioid use and its extreme form, opioid use disorder (OUD). Buprenorphine is one of the few medications available for the management of patients with co-occurring OUD and chronic pain. Care for these patients can be challenging and require the expertise of specialist clinicians with a deep understanding of addiction and cancer pain. Regrettably, these specialist clinicians may not always be available and accessible when patients are admitted to the hospital. Reports on how primary non-specialist clinicians without access to specialist addiction services navigate the care of such patients in the inpatient setting are limited. We hereby describe the care of three patients with OUD receiving buprenorphine who were hospitalized for cancer pain.
MattiuzziC, LippiG. Current cancer epidemiology. J Epidemiol Glob Health, 2019; 9(4):217–222.
3.
YennurajalingamS, ArthurJ, ReddyS, et al.Frequency of and factors associated with nonmedical opioid use behavior among patients with cancer receiving opioids for cancer pain. JAMA Oncol, 2021; 7(3):404–411.
4.
ArthurJA, TangM, LuZ, et al.Random urine drug testing among patients receiving opioid therapy for cancer pain. Cancer, 2020; 127(6):968–975.
5.
MorylN, MalhotraVT. A case for palliative care and addiction specialists collaboration and joint research. JAMA Netw Open, 2021; 4(12):e2143436.
6.
MerlinJS, YoungSR, ArnoldR, et al.Managing opioids, including misuse and addiction, in patients with serious illness in ambulatory palliative care: A qualitative study. Am J Hosp Palliat Care, 2020; 37(7):507–513.
7.
NiaziSK, SpauldingA, BrennanE, et al.Mental health and chemical dependency services at US cancer centers. J Natl Compr Canc Netw, 2021; 19(7):829–838.
8.
MerlinJS, KhodyakovD, ArnoldR, et al.Expert panel consensus on management of advanced cancer-related pain in individuals with opioid use disorder. JAMA Netw Open, 2021; 4(12):e2139968.
9.
AhmedS, BhivandkarS, LonerganBB, et al.Microinduction of buprenorphine/naloxone: A review of the literature. Am J Addict, 2021; 30(4):305–315.
10.
WallensteinSL, KaikoRF, RogersAG, et al.Clinical analgesic assay of sublingual buprenorphine and intramuscular morphine. NIDA Res Monogr, 1982; 41:288–293.
NielsenS, DegenhardtL, HobanB, et al.A synthesis of Oral Morphine Equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf, 2016; 25(6):733–737.
13.
CoeMA, LofwallMR, WalshSL. Buprenorphine pharmacology review: Update on transmucosal and long-acting formulations. J Addict Med, 2019; 13(2):93–103.
14.
DalalS, ChitneniA, BergerAA, et al.Buprenorphine for chronic pain: A safer alternative to traditional opioids. Health Psychol Res, 2021; 9(1):27241.
15.
Janet HoJ, JonesKF, SagerZ, et al.Barriers to buprenorphine prescribing for opioid use disorder in hospice and palliative care. J Pain Symptom Manage, 2022; 64(2):119–127.
SigmonSC. The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry, 2015; 72(4):395–396.
18.
LeFevreN, St LouisJ, WorringerE, et al.The end of the X-waiver: Excitement, apprehension, and opportunity. J Am Board Fam Med, 2023; 36(5):867–872.
19.
EnglanderH, PriestKC, SnyderH, et al.A call to action: Hospitalists’ role in addressing substance use disorder. J Hosp Med, 2020; 15(3):184–187.
20.
HarrisMTH, PeterkinA, BachP, et al.Adapting inpatient addiction medicine consult services during the COVID-19 pandemic. Addict Sci Clin Pract, 2021; 16(1):13.
21.
ComptonWM, JonesCM, BaldwinGT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med, 2016; 374(2):154–163.
22.
VowlesKE, McEnteeML, JulnesPS, et al.Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis. Pain, 2015; 156(4):569–576.
23.
KidorfM, DisneyER, KingVL, et al.Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend, 2004; 74(2):115–122.
24.
JonesCM, McCance-KatzEF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend, 2019; 197:78–82.
25.
ArthurJA, EdwardsT, LuZ, et al.Interdisciplinary intervention for the management of nonmedical opioid use among patients with cancer pain. Cancer, 2022; 128(20):3718–3726.
26.
Fitzgerald JonesK, KhodyakovD, ArnoldR, et al.Consensus-based guidance on opioid management in individuals with advanced cancer-related pain and opioid misuse or use disorder. JAMA Oncol, 2022; 8(8):1107–1114.
